C. Zhou , S. Ren , J. Chen , X. Xu , Y. Cheng , G. Chen , Y. Pan , Y. Fang , Q. Wang , Y. Huang , W. Yao , R. Wang , X. Li , W. Zhang , Y. Zhang , S. Hu , R-H. Guo , D. Wang , Z. Wang , X. Lu
{"title":"12P: Camrelizumab联合化疗(Cam-chemo)作为晚期鳞状非小细胞肺癌(sqNSCLC)的一线(1L)治疗:来自III期CameL-sq试验的5y更新","authors":"C. Zhou , S. Ren , J. Chen , X. Xu , Y. Cheng , G. Chen , Y. Pan , Y. Fang , Q. Wang , Y. Huang , W. Yao , R. Wang , X. Li , W. Zhang , Y. Zhang , S. Hu , R-H. Guo , D. Wang , Z. Wang , X. Lu","doi":"10.1016/S1556-0864(25)00207-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S16-S17"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"12P: Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial\",\"authors\":\"C. Zhou , S. Ren , J. Chen , X. Xu , Y. Cheng , G. Chen , Y. Pan , Y. Fang , Q. Wang , Y. Huang , W. Yao , R. Wang , X. Li , W. Zhang , Y. Zhang , S. Hu , R-H. Guo , D. Wang , Z. Wang , X. Lu\",\"doi\":\"10.1016/S1556-0864(25)00207-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S16-S17\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086425002072\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425002072","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
12P: Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.